Literature DB >> 15356102

Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells.

Rima Koka1, Patrick Burkett, Marcia Chien, Sophia Chai, David L Boone, Averil Ma.   

Abstract

NK cells protect hosts against viral pathogens and transformed cells, and dendritic cells (DCs) play important roles in activating NK cells. We now find that murine IL-15Ralpha-deficient DCs fail to support NK cell cytolytic activity and elaboration of IFN-gamma, despite the fact that these DCs express normal levels of costimulatory molecules and IL-12. By contrast, IL-15Ralpha expression on NK cells is entirely dispensable for their activation by DCs. In addition, blockade with anti-IL-15Ralpha and anti-IL-2Rbeta but not anti-IL-2Ralpha-specific Abs prevents NK cell activation by wild-type DCs. Finally, presentation of IL-15 by purified IL-15Ralpha/Fc in trans synergizes with IL-12 to support NK cell priming. These findings suggest that murine DCs require IL-15Ralpha to present IL-15 in trans to NK cells during NK cell priming. Copyright 2004 The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356102     DOI: 10.4049/jimmunol.173.6.3594

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  83 in total

1.  Flt3 permits survival during infection by rendering dendritic cells competent to activate NK cells.

Authors:  Céline Eidenschenk; Karine Crozat; Philippe Krebs; Ramon Arens; Daniel Popkin; Carrie N Arnold; Amanda L Blasius; Chris A Benedict; Eva Marie Y Moresco; Yu Xia; Bruce Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-10       Impact factor: 11.205

Review 2.  Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything.

Authors:  A Loewendorf; C A Benedict
Journal:  J Intern Med       Date:  2010-05       Impact factor: 8.989

Review 3.  Tolerogenic dendritic cells and their potential applications.

Authors:  Jim Hu; Yonghong Wan
Journal:  Immunology       Date:  2011-01-05       Impact factor: 7.397

4.  The genetic background influences the cellular and humoral immune responses to vaccines.

Authors:  M Zeng; E Nourishirazi; E Guinet; M Nouri-Shirazi
Journal:  Clin Exp Immunol       Date:  2016-08-16       Impact factor: 4.330

5.  Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.

Authors:  Meili Zhang; Wei Ju; Zhengsheng Yao; Ping Yu; Bih-Rong Wei; R Mark Simpson; Rebecca Waitz; Marcella Fassò; James P Allison; Thomas A Waldmann
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

6.  Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs.

Authors:  Guido Ferlazzo; Maggi Pack; Dolca Thomas; Casper Paludan; Dorothee Schmid; Till Strowig; Gwenola Bougras; William A Muller; Lorenzo Moretta; Christian Münz
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-09       Impact factor: 11.205

7.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

8.  Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine.

Authors:  Cary Hsu; Marybeth S Hughes; Zhili Zheng; Regina B Bray; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

Review 9.  Recent advances in dendritic cell biology.

Authors:  Sylvia Adams; David W O'Neill; Nina Bhardwaj
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

10.  Survival adjustment of mature dendritic cells by IL-15.

Authors:  Sigrid P Dubois; Thomas A Waldmann; Jürgen R Müller
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.